AUNA (AUNA) Q2 2024: EBITDA Margin Expands 200bps as Peru and Colombia Drive Operating Leverage

2024-08-21 | By EarningsIQ Research

AUNA’s Q2 results underscore the power of its integrated healthcare model, with Peru and Colombia delivering robust margin expansion and cash flow discipline even as Mexico’s ramp remains gradual. Margin gains, physician productivity, and high-complexity service mix are reshaping the portfolio, while management signals long runway ahead in fragmented Latin American healthcare. Investors should watch for Mexico’s high-complexity ramp and OncoMexico’s commercial traction in the back half.

Summary

• Margin Expansion Anchored by Peru and Colombia: Scalable platform and high-complexity mix drive EBITDA leverage.
• Mexico’s Gradual Ramp: Physician recruitment and bundled services show early momentum, but scale-up remains deliberate.
• Long-Term Growth Runway: Management emphasizes 1% market share and significant opportunity in Latin America’s private healthcare.

Business Overview

AUNA operates a diversified, vertically and horizontally integrated healthcare platform across Peru, Colombia, and Mexico. The company generates revenue from hospital services, healthcare plans (insurance), and specialty oncology offerings. Its business is segmented by geography, with Peru and Colombia as mature, scaled markets, and Mexico as a developing growth vector. The model leverages owned hospitals, direct physician relationships, and bundled care solutions to drive volume and margin, particularly in high-complexity services such as oncology, neurosurgery, and trauma.

Performance Analysis

AUNA delivered double-digit top-line growth, with consolidated revenue up 13% FX-neutral, primarily driven by Peru and Colombia. Adjusted EBITDA rose 25% on an FX-neutral basis, and the company’s EBITDA margin expanded by 200 basis points, reaching 22.1%. Margin expansion was underpinned by operating leverage in Peru (21% margin) and resilient profitability in Mexico (33% margin), despite ongoing investments. Colombia’s margin held at 15.3% as high-complexity services and occupancy gains offset regulatory headwinds and increased impairment recognition.

Cash flow from operations remained solid, with capex disciplined at sub-$50 million guidance for the year. Leverage continued its downward trajectory, with net debt to EBITDA at 4.13x, on track with management’s medium-term deleveraging target. The quarter included a one-off payout related to a prior acquisition earn-out, which temporarily impacted free cash flow, but underlying conversion metrics remained stable.

• Peru Margin Lift: Integrated model and high-complexity mix sustained 21% margin, with plan price adjustments and SG&A discipline supporting profitability.
• Colombia Occupancy Surge: Six-point occupancy gain (to 81%) and high-complexity mix drove 18% revenue growth, with cash flow prioritized amid regulatory uncertainty.
• Mexico’s Mixed Signals: Revenue grew 3% on high-complexity services, but occupancy was flat and EBITDA margin stable as investments and SG&A normalization continued.

Segment performance reflects a portfolio in transition: Peru and Colombia provide predictable growth and margin, while Mexico’s gradual ramp and OncoMexico launch are key to future scale and diversification.

Executive Commentary

Strategic Positioning

1. Integrated Platform Drives Margin and Scale

AUNA’s vertically integrated model—combining hospitals, insurance, and specialty care—continues to deliver operating leverage, particularly in Peru where high-complexity services and plan cross-selling have unlocked durable margin gains. The company’s regional scale enables synergy capture, SG&A efficiency, and rapid deployment of best practices across markets.

2. Mexico: Gradual Ramp, Physician Model, and OncoMexico Launch

Mexico remains a multi-year growth bet, with the Monterrey platform focused on high-complexity physician recruitment, bundled service innovation, and the pilot launch of OncoMexico, the country’s first integrated oncology insurance. Early results show physician productivity and bundled solutions gaining traction, but management frames the ramp as deliberate and expects more pronounced gains in the second half and into 2025.

3. Portfolio Mix Shift Toward High Complexity

Across all geographies, the business is shifting toward higher-margin, high-complexity services—such as neurosurgery, trauma, and oncology— which drive both revenue growth and margin expansion. Physician “hunting” and productivity initiatives are designed to increase volume in these specialties and support cross-selling of adjacent services.

4. Cash Flow Discipline and Deleveraging

Management remains focused on cash flow generation and disciplined capex, targeting sub-$50 million annual investment. The deleveraging path is on track, with no plans for dividends until net leverage reaches 3x, and a continued emphasis on reinvestment over capital returns.

5. Regulatory and Market Navigation

Colombia’s regulatory volatility is being managed via conservative working capital practices and risk-adjusted growth, with management prioritizing collections and stable receivable days. In Peru, pricing flexibility and internal transfer pricing adjustments ensure MLR (medical loss ratio) remains within target ranges despite policy changes.

Key Considerations

This quarter’s results highlight the strengths and challenges of AUNA’s multi-market, integrated healthcare approach. Investors should contextualize growth and margin trends against the company’s deliberate portfolio mix shift and capital allocation priorities.

Key Considerations:

• Margin Expansion Sustainability: Peru’s 21% margin and Colombia’s 15.3% reflect mature scale, but further gains depend on high-complexity mix and SG&A discipline.
• Mexico Ramp and OncoMexico Pilot: Early physician recruitment and bundled services are promising, but the full financial impact will materialize gradually.
• Cash Flow and Capex Management: One-off acquisition payments aside, operating cash flow covers interest, with capex capped and deleveraging on track.
• Regulatory Headwinds in Colombia: Conservative growth and impairment recognition mitigate risk, but market volatility could affect working capital and collections.
• Long-Term Market Opportunity: Management’s emphasis on 1% market share signals a large, underpenetrated TAM (total addressable market) in Latin America.

Risks

Regulatory risk in Colombia remains material, as healthcare reform uncertainty and payer intervention could disrupt collections or margin stability. Mexico’s ramp is exposed to execution risk, particularly in physician recruitment and bundled product adoption. Currency volatility and one-off acquisition obligations also introduce earnings variability. Management’s focus on cash flow and risk-adjusted growth partially mitigates these exposures, but any macro or policy shock in core markets would impact results.

Forward Outlook

For Q3 2024, AUNA guided to:

• Continued double-digit EBITDA growth, with margin expansion led by Peru and Colombia
• Mexico growth to accelerate in H2 as high-complexity initiatives mature

For full-year 2024, management reaffirmed guidance:

• At least 20% adjusted EBITDA growth (FX-neutral)

Management highlighted:

• Peru will remain the primary growth driver in 2024
• OncoMexico and bundled services in Monterrey are expected to scale in 2025 and beyond

Takeaways

AUNA’s integrated model continues to deliver margin and cash flow gains, with Peru and Colombia providing stability and Mexico offering asymmetric upside. The company’s focus on high-complexity services, disciplined capex, and long-term market penetration positions it well, but execution in Mexico and regulatory risk in Colombia remain key watchpoints.

• Margin and Mix: Margin expansion and high-complexity mix are driving operating leverage, especially in Peru and Colombia.
• Mexico Execution: Physician recruitment and OncoMexico’s pilot are critical to unlocking scale and diversification in the next phase.
• Watch for: H2 Mexico ramp, OncoMexico’s commercial traction, and regulatory developments in Colombia.

Conclusion

AUNA’s Q2 results validate its scalable, integrated model and disciplined capital allocation, with mature markets driving margin and cash flow gains. The next leg of growth hinges on Mexico’s ramp and successful execution of bundled, high-complexity services as the company targets a much larger share of Latin America’s private healthcare market.

Industry Read-Through

AUNA’s results underscore the growing importance of integrated, high-complexity healthcare platforms in Latin America, as payers and patients seek bundled solutions and value-based care. Margin expansion through scale and service mix is likely to become a defining theme for regional operators. Regulatory risk in Colombia and gradual adoption curves in new markets like Mexico serve as reminders that execution and policy navigation are critical. Competitors and investors should note the operational leverage available from bundled care, physician integration, and insurance cross-sell in fragmented, underpenetrated markets.

AUNA Healthcare Latin America Margin Expansion Integrated Care Oncology Deleveraging Growth